Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1985-7-11
pubmed:abstractText
The kinetics of morphine and formation of the main metabolite, morphine-3-glucuronide (M3G) after single and intravenous doses of morphine were studied in six cancer patients and compared with the formation rate of M3G in vitro in microsomes isolated from liver biopsies obtained from the same patients at palliative laparotomy. The results showed that high formation rates of M3G in vitro in microsomes isolated from liver biopsies were associated both with high apparent oral clearance values and high M3G/morphine AUC (area under the concentration vs time curve) ratios as measured in vivo in the same patients. In accordance with previous results marked interindividual differences were seen in the kinetics of morphine; the oral bioavailability varied between 30 and 69% and the systemic plasma clearance between 18.6 and 34.0 ml min-1 kg-1. This variation correlated with the variation in morphine metabolism as assessed in vitro. In vivo, a high M3G/morphine AUC ratio predicted a high oral clearance. Hepatic UDP-glucuronyl transferase activity is thus an important determinant of the in vivo kinetics of orally administered morphine.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-103726, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-1204496, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-13954, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-18313, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-235634, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-4843237, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-6410141, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-6813127, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-6849780, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-6882627, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7046329, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7059434, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7107787, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7122112, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7297022, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-731414, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-7340879, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-833759, http://linkedlifedata.com/resource/pubmed/commentcorrection/3994897-83392
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
495-501
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.
pubmed:publicationType
Journal Article, Comparative Study, In Vitro, Research Support, Non-U.S. Gov't